Introduction In the domain of oncology, immunotherapy has emerged as a pioneering methodology, harnessing the body's immune system to combat malignant tumors. There are many immunotherapeutic approaches, but Chimeric Antigen Rece..
Introduction Cytokine Release Syndrome (CRS) is an immune system overreaction triggered by therapies like immunotherapy or CAR-T cell treatment. It prompts an influx of cytokines, causing symptoms ranging from fever to potentiall..
Patients undergoing outpatient CAR T-cell therapy for cancer must be cared for by a multidisciplinary team that includes nurse coordinators, according to a poster presented at the 49th Annual Oncology Nursing Society Conference. ..
Introduction CAR T cell therapy, an innovative form of immunotherapy, has demonstrated exceptional efficacy in the treatment of specific tumors by leveraging the potency of a patient's own immune system. Recently, scientists have..
Feb 2024: China's pioneering efforts in creating breakthrough cancer therapeutics have gained traction with the introduction of chimeric antigen receptor (CAR)-engineered T-cell (CAR T) therapy for multiple myeloma, a devastatin..
Discover the magic of CAR-T treatment! Read our blog on patient selection for CAR T therapy. Are you the ideal candidate for this innovative cancer treatment? Find out and begin your personalized journey to cancer recovery. He..
The revolutionary CAR T Cell Therapy is changing the scenario of how we deal with cancer, making it more personal and powerful. This latest therapy uses a patient's own immune cells and genetically modifies them to target and des..
مه 2023: درمان با سلول T با گیرنده آنتی ژن کایمریک (CAR) یک پیشرفت نوآورانه در زمینه درمان سرطان فردی است. سلولهای T خود بیمار در طول فرآیند تولید اصلاح ژنتیکی میشوند تا بیان کنند.
مارس 2023: اولین فصل از خاطرات سام نیل برای کسی که هیچ اطلاع قبلی از آن نداشت، شوک بزرگی خواهد بود. به اندازه کافی خنده دار شروع می شود: یک کاموای عالی درباره دخترش النا که در مورد جو پدرش سوال شده است.
مارس 2023: خلاصه کوتاه: هدف از این کارآزمایی بالینی این است که بفهمد آیا میتوان از درمان با سلول T با گیرنده آنتی ژن ضد MESO برای درمان سرطان تخمدان اپیتلیال که برگشته یا به سایر موارد دیگر پاسخ نمیدهد استفاده کرد.